Myriad Genetics (MYGN) Misses Q1 EPS by 7c; Maintains Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Jefferies Maintains 'Hold' Rating on Myriad Genetics (MYGN) Post Q1, Estimates Lowered
November 5, 2014 8:42 AM ESTJefferies lowered estimates while maintaining a Hold rating and $37 price target on Myriad Genetics (NASDAQ: MYGN) following Q1 results.
Analyst Brandon Couillard commented, "MYGN's 1Q15 results were in line with its recent pre-release, but its initial 2Q guidance also fell well below... More
